Herlev Hospital | Nephrology Department
Status and phase
Conditions
Treatments
About
This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
HER2-Expressing Breast Cancer-Specific Inclusion Criteria
HER2-Expressing Gastric/Gastroesophageal (GEJ) Cancer-Specific Inclusion Criteria
HER2-Positive Solid Tumor Specific Inclusion Criteria
Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
537 participants in 2 patient groups
Loading...
Central trial contact
Reference Study ID Number: GO40311 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal